Read Full Article
ROCKVILLE, Md. -- REGENXBIO Inc. , a leading biotechnology company in gene therapy, today announced the appointment of David C. Stump, M.D., to its board of directors...
David's expertise in clinical research and development, as well as his experience advancing therapies through the regulatory process to FDA approval, will be of great value as REGENXBIO prepares to advance gene therapy treatments into the clinic.
REGENXBIO's proprietary NAV Technology Platform has generated gene therapy treatments with the potential to transform the lives of patients suffering from severe diseases with significant unmet medical needs.